Table 1.
Demographic Data and Clinical Characteristics of the Patients
| Characteristic | All Patients (n=105) | IA (n=55) | CPA (n=37) | ABPA (n=12) | Aspergillus fumigatus (n=80)* | Non-fumigatus Aspergillus (n=30)* |
|---|---|---|---|---|---|---|
| Age, y, median (IQR) | 65 (52–72) | 67 (53–73) | 66 (54–70) | 54 (35–63) | 66 (52–72) | 62 (52–71) |
| Male sex | 79 (75.2) | 43 (78.2) | 29 (78.4) | 7 (58.3) | 61 (76.3) | 22 (73.3) |
| Underlying diseases | ||||||
| Chronic lung diseases | ||||||
| COPD | 15 (14.3%) | 2 (3.6%) | 10 (27.0%) | 3 (25.0%) | 13 (16.3%) | 3 (30.0%) |
| Bronchiectasis | 19 (18.1%) | 1 (1.8%) | 14 (37.8%) | 4 (33.3%) | 16 (20.0%) | 4 (13.3%) |
| Asthma | 4 (3.8%) | 1 (1.8%) | 0 (0.0%) | 3 (25.0%) | 4 (5.0%) | 1 (3.3%) |
| Prior pulmonary tuberculosis | 11 (10.5%) | 1 (1.8%) | 9 (24.3%) | 1 (8.3%) | 10 (12.5%) | 2 (6.7%) |
| Malignancies | ||||||
| Lung cancer | 15 (14.3%) | 11 (20.0%) | 3 (8.1%) | 1 (8.3%) | 10 (12.5%) | 6 (20.0%) |
| Other solid tumors | 6 (5.7%) | 4 (7.3%) | 2 (5.4%) | 0 (0.0%) | 4 (5.0%) | 2 (6.7%) |
| Hematologic malignancies | 6 (5.7%) | 5 (9.1%) | 1 (2.7%) | 0 (0.0%) | 4 (5.0%) | 2 (6.7%) |
| Transplantation | ||||||
| Liver transplantation | 14 (13.3%) | 13 (23.6%) | 0 (0.0%) | 0 (0.0%) | 12 (15.0%) | 2 (6.7%) |
| Kidney transplantation | 1 (1.0%) | 1 (1.8%) | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) | 0 (0.0%) |
| Heart transplantation | 5 (4.8%) | 5 (9.1%) | 0 (0.0%) | 0 (0.0%) | 5 (6.3%) | 0 (0.0%) |
| Hematopoietic cell transplantation | 2 (1.9%) | 2 (3.6%) | 0 (0.0%) | 0 (0.0%) | 2 (2.5%) | 0 (0.0%) |
| Diabetes | 13 (2.9%) | 5 (9.1%) | 7 (18.9%) | 0 (0.0%) | 13 (16.3%) | 1 (3.3%) |
| Autoimmune diseases | 15 (14.3%) | 10 (18.2%) | 5 (13.5%) | 0 (0.0%) | 9 (11.3%) | 6 (20.0%) |
| Chronic renal failure | 10 (9.5%) | 9 (16.4%) | 1 (2.7%) | 0 (0.0%) | 9 (11.3%) | 2 (6.7%) |
| Multiple organ dysfunction syndrome | 7 (6.7%) | 7 (12.7%) | 0 (0.0%) | 0 (0.0%) | 6 (7.5%) | 2 (6.7%) |
| Prior azole therapy | 15 (14.3%) | 3 (5.5%) | 9 (24.3%) | 3 (25.0%) | 12 (15.0%) | 4 (13.3%) |
| Hospital admission | 99 (94.3%) | 55 (100.0%) | 33 (89.2%) | 10 (83.3%) | 77 (96.3%) | 27 (90.0%) |
| ICU admission | 40 (38.1%) | 38 (69.1%) | 1 (2.7%) | 0 (0.0%) | 31 (38.8%) | 11 (36.7%) |
| Antifungal therapy | 102 (97.1%) | 54 (98.2%) | 37 (100.0%) | 10 (83.3%) | 77 (96.3%) | 30 (100.0%) |
| Mortality | 37 (35.2%) | 34 (61.8%) | 3 (8.1%) | 0 (0.0%) | 30 (37.5%) | 9 (30.0%) |
Notes: *Five patients were coinfected by both A. fumigatus and non-fumigatus Aspergillus.
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; CPA, chronic pulmonary aspergillosis; IA, invasive aspergillosis; ICU: intensive care unit; IQR, interquartile range.